Hipertensión pulmonar

Pulmonary hypertension is a rare, underdiagnosed disease characterized by highly nonspecific clinical manifestations and an estimated latency period of at least two years from symptoms onset to diagnostic confirmation. Therefore, a high degree of clinical suspicion is necessary to facilitate early detection, provide the patient with appropriate treatment, and improve prognosis. Its definitive confirmation requires a right heart catheterization. The primary goal of treatment is always to achieve low risk. If this cannot be attained through pharmacological measures, alternative options such as lung transplantation can be considered for eligible patients. New molecular pathways, such as the activin/BMPR axis, have been studied with a novel emerging drug called sotatercept.